News Search Results
Jan 26, 2026, 08:30 ET Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease
More news about: Immusoft
Jan 26, 2026, 07:45 ET BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
Notes may be made only by means of an offering memorandum.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jan 26, 2026, 07:04 ET Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson's Disease
NIJMEGEN, The Netherlands, Jan. 26, 2026 /PRNewswire/ -- Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative diseases, today announced a scientific collaboration with Radboud University
More news about: Mair Therapeutics
Jan 26, 2026, 07:00 ET Divamics Showcases Lead Autoimmune Program DVI-001 and Unveils New Metabolic Program DVI-004 at JPM Week 2026
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech
More news about: Divamics
Jan 26, 2026, 07:00 ET Origin Agritech to Hold Business Update & Fiscal Year 2025 Earnings Conference Call on Monday, February 2 at 8 a.m. ET
first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Jan 26, 2026, 02:00 ET HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract
More news about: HanchorBio Inc.
Jan 25, 2026, 19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 25, 2026, 19:00 ET Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a)
BOSTON, Jan. 25, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that the first patient has been dosed in a global Phase 2b clinical
More news about: Argo Biopharmaceutical Co., Ltd
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
LinkedIn.5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Jan 23, 2026, 08:30 ET Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
60 to 200 molecules synthesized and tested in each program.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 23:40 ET 晶泰科技賦能萊芒生物取得細胞療法重大成果，以1‰劑量CAR-T實現多位系統性紅斑狼瘡完全緩解出院
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術META 10展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology、Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。目前公司發展迅速，70% 高層次研發人員來自國內外名校並具有豐富的產業化經驗，多條研發管線進展順利。其中代謝增強型 CAR-T 細胞治療正在開展
More news about: 晶泰科技
Jan 22, 2026, 10:45 ET Medical Electrodes Market Surges to USD 5.2 Billion by 2033, Propelled by 5.5% CAGR - Verified Market Reports®
Global Laboratory Information Management System/LIMS Market Size By Deployment Type (On Premise, Cloud Based), By End User (Pharmaceuticals, Biotechnology), By Software Type (Sample Management, Data Management), By Application (Clinical Research, Quality Assurance), By Distribution Channel (Direct Sales,
More news about: Verified Market Reports
Jan 22, 2026, 10:30 ET Next-Generation Sequencing Market worth $29.53 billion by 2030 | MarketsandMarkets™
sequencing market in 2024.The next-generation sequencing market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, clinical and diagnostic laboratories, and other end users. Academic and research institutes held the largest share of the next-generation
More news about: MarketsandMarkets
Jan 22, 2026, 09:37 ET Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
wet-lab validation through Insilico's automated assay platforms.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 22, 2026, 09:11 ET COGNIZIN® CITICOLINE NAMED "FUNCTIONAL INGREDIENT TO WATCH IN 2026" BY MINTEL & BLACK SWAN DATA, SHOWCASING ITS EXPLOSIVE GROWTH IN THE BRAIN HEALTH CATEGORY
— Cognizin® —About Kyowa Hakko USAKyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to
More news about: Kyowa Hakko U.S.A
Jan 22, 2026, 09:00 ET Global Biopharma Company Triples Research Commitment to Tishman Speyer and Breakthrough Properties' One Milestone at the Harvard Enterprise Research Campus, One of Boston's Most Anticipated New Developments
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Jan 22, 2026, 07:00 ET PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader
while maintaining favorable safety and combinability profiles.About PAQ TherapeuticsPAQ Therapeutics is a clinical-stage biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.
More news about: PAQ Therapeutics
Jan 22, 2026, 06:00 ET PhotonPharma Inc. Appoints Vaccine Innovation Leader William Warren, Ph.D. to Board of Directors
the appointment of William Warren, Ph.D., to its Board of Directors, effective immediately. Dr. Warren brings over three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide PhotonPharma's strategic initiatives and growth trajectory.
More news about: PhotonPharma Inc.
Jan 22, 2026, 05:00 ET New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
months.7,8NERLYNX is being made available in Thailand by independent pharmaceutical company, Specialised Therapeutics (ST), under exclusive license from Puma Biotechnology, Inc. (Nasdaq: PBYI).ST Chief Executive Officer, Mr Carlo Montagner, said NERLYNX is the first therapy the company is launching in Thailand
More news about: Specialised Therapeutics
Jan 21, 2026, 18:00 ET BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
driving continued growth and improving patient lives and outcomes."About BioTissue Holdings, Inc. BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic
More news about: BioTissue Holdings, Inc.
Jan 21, 2026, 10:00 ET Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 21, 2026, 09:17 ET Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format
VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced the initiation of a pilot production run of non-nicotine, caffeine-based energy pouches under its wholly
More news about: Doseology Sciences Inc.
Jan 21, 2026, 09:05 ET Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Dr. Quay earned this recognition for his leadership in advancing innovative biotechnology solutions and building a high-performing, people-centered organization. As a physician-scientist and entrepreneur, he has guided the development
More news about: Atossa Therapeutics Inc
Jan 21, 2026, 09:05 ET ISPE Announces Radiopharmaceuticals Community of Practice
share knowledge to accelerate the growth of the industry. The CoP will also work synergistically with other ISPE CoPs, such as those focusing on biotechnology, containment, critical utilities, disposables/single-use technologies, sterile products processing, oral solid dosage, sustainability, HVAC, and
More news about: ISPE
Jan 21, 2026, 08:39 ET DIA Launches ASCENT Platform and LIFT Biotech & Startup Program to Accelerate Emerging Innovation
DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its inaugural initiative, the
More news about: Drug Information Association